Skip to main content

Advertisement

SpringerLink
Log in

Glucocorticoid-induced osteoporosis: 2019 concise clinical review

  • Concise Clinical Review
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Glucocorticoids remain widely used for many medical conditions, and fractures are the most serious common adverse event related to long-term glucocorticoid use. Glucocorticoid-induced osteoporosis (GIOP) develops in a time- and dose-dependent manner, but even at low doses, an increased risk of fragility fracture may be observed even within the first month of treatment. GIOP is mediated by multiple pathophysiologic mechanisms resulting in an inhibition of bone formation and an increase in bone resorption. The clinical assessment of GIOP has potential pitfalls since dual-energy X-ray absorptiometry (DXA) may underestimate the risk of fracture in patients treated with glucocorticoids. Many national organizations have developed guidelines for assessing fracture risk and treating patients with, or at risk for, GIOP. These groups advocate both antiresorptive agents and bone-forming agents based predominately on their efficacy in improving bone mineral density. Oral bisphosphonates are generally the first-line therapy for GIOP in most patients due to their proven efficacy, good safety, and low cost. For those patients at greater risk of fracture, teriparatide should be considered earlier, based on its ability to significantly reduce vertebral fractures when compared with alendronate. GIOP remains a major public health concern that is at least partially preventable with current and potential future therapeutic options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Overman RA, Yeh J-Y, Deal CL (2013) Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken) 65:294–298. https://doi.org/10.1002/acr.21796

    Article  Google Scholar 

  2. Walsh LJ, Wong CA, Pringle M, Tattersfield AE (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313:344–346. https://doi.org/10.1136/bmj.313.7053.344

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Mudano A, Allison J, Hill J et al (2001) Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol 28:1298–1305

    CAS  PubMed  Google Scholar 

  4. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96:115–123. https://doi.org/10.1016/0002-9343(94)90131-7

    Article  CAS  PubMed  Google Scholar 

  5. Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM (2016) Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int 27:1709–1718. https://doi.org/10.1007/s00198-015-3455-9

    Article  CAS  PubMed  Google Scholar 

  6. Roux C, Briot K (2017) Imminent fracture risk. Osteoporos Int 28:1765–1769. https://doi.org/10.1007/s00198-017-3976-5

    Article  CAS  PubMed  Google Scholar 

  7. Amiche MA, Abtahi S, Driessen JHM, Vestergaard P, de Vries F, Cadarette SM, Burden AM (2018) Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos 13:30. https://doi.org/10.1007/s11657-018-0424-x

    Article  PubMed  PubMed Central  Google Scholar 

  8. Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O’Malley CD, Saag K, Curtis JR (2016) Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int 27:3239–3249. https://doi.org/10.1007/s00198-016-3646-z

    Article  CAS  PubMed  Google Scholar 

  9. van Staa TP, Leufkens HG, Abenhaim L et al (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383–1389. https://doi.org/10.1093/rheumatology/39.12.1383

    Article  Google Scholar 

  10. Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000. https://doi.org/10.1359/jbmr.2000.15.6.993

    Article  PubMed  Google Scholar 

  11. Paskins Z, Whittle R, Sultan AA, Muller S, Blagojevic-Bucknall M, Helliwell T, Hider S, Roddy E, Mallen C (2018) Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study. BMC Med 16:4. https://doi.org/10.1186/s12916-017-0987-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bultink IEM, Harvey NC, Lalmohamed A, Cooper C, Lems WF, van Staa TP, de Vries F (2014) Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int 25:1275–1283. https://doi.org/10.1007/s00198-013-2587-z

    Article  CAS  PubMed  Google Scholar 

  13. Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop D, Rairie JE, Fitzgerald S, Manzi S (1999) Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 42:882–890. https://doi.org/10.1002/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C

    Article  CAS  PubMed  Google Scholar 

  14. Casagrande SS, Cowie CC, Malozowski S (2017) Glucocorticoid use and its association with skeletal health among U.S. adults with diabetes. J Diabetes Complicat 31:353–357. https://doi.org/10.1016/j.jdiacomp.2016.06.021

    Article  Google Scholar 

  15. Graat-Verboom L, van den Borne BEEM, Smeenk FWJM, Spruit MA, Wouters EFM (2011) Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res 26:561–568. https://doi.org/10.1002/jbmr.257

    Article  PubMed  Google Scholar 

  16. Lu P-C, Yang Y-H, Guo S-E, Yang T-M (2017) Factors associated with osteoporosis in patients with chronic obstructive pulmonary disease-a nationwide retrospective study. Osteoporos Int 28:359–367. https://doi.org/10.1007/s00198-016-3732-2

    Article  PubMed  Google Scholar 

  17. Okazaki R, Watanabe R, Inoue D (2016) Osteoporosis associated with chronic obstructive pulmonary disease. J Bone Metab 23:111–120. https://doi.org/10.11005/jbm.2016.23.3.111

    Article  PubMed  PubMed Central  Google Scholar 

  18. Jones A, Fay JK, Burr ML, Stone M, Hood K, Roberts G, Cochrane Airways Group (2002) Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003537

  19. Suissa S, Baltzan M, Kremer R, Ernst P (2004) Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 169:83–88. https://doi.org/10.1164/rccm.200305-640OC

    Article  PubMed  Google Scholar 

  20. Hubbard R, Tattersfield A, Smith C, West J, Smeeth L, Fletcher A (2006) Use of inhaled corticosteroids and the risk of fracture. Chest 130:1082–1088. https://doi.org/10.1378/chest.130.4.1082

    Article  CAS  PubMed  Google Scholar 

  21. Diederich S, Eigendorff E, Burkhardt P, Quinkler M, Bumke-Vogt C, Rochel M, Seidelmann D, Esperling P, Oelkers W, Bähr V (2002) 11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 87:5695–5701. https://doi.org/10.1210/jc.2002-020970

    Article  CAS  PubMed  Google Scholar 

  22. Wu Z, Bucher NL, Farmer SR (1996) Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol Cell Biol 16:4128–4136. https://doi.org/10.1128/MCB.16.8.4128

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R (2005) Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329:177–181. https://doi.org/10.1016/j.bbrc.2005.01.117

    Article  CAS  PubMed  Google Scholar 

  24. Hayashi K, Yamaguchi T, Yano S, Kanazawa I, Yamauchi M, Yamamoto M, Sugimoto T (2009) BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 379:261–266. https://doi.org/10.1016/j.bbrc.2008.12.035

    Article  CAS  PubMed  Google Scholar 

  25. Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC (2011) Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem 286:44326–44335. https://doi.org/10.1074/jbc.M111.283481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Mazziotti G, Formenti AM, Adler RA, Bilezikian JP, Grossman A, Sbardella E, Minisola S, Giustina A (2016) Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines. Endocrine 54:603–611. https://doi.org/10.1007/s12020-016-1146-8

    Article  CAS  PubMed  Google Scholar 

  27. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM (2003) Mechanisms of TNF-α– and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Investig 111:821–831. https://doi.org/10.1172/JCI16069

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Dovio A, Perazzolo L, Saba L, Termine A, Capobianco M, Bertolotto A, Angeli A (2006) High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. Eur J Endocrinol 154:745–751. https://doi.org/10.1530/eje.1.02147

    Article  CAS  PubMed  Google Scholar 

  29. Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y (2003) Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem 278:44667–44674. https://doi.org/10.1074/jbc.M300213200

    Article  CAS  PubMed  Google Scholar 

  30. Weinstein RS, Wan C, Liu Q, Wang Y, Almeida M, O’Brien CA, Thostenson J, Roberson PK, Boskey AL, Clemens TL, Manolagas SC (2010) Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell 9:147–161. https://doi.org/10.1111/j.1474-9726.2009.00545.x

    Article  CAS  PubMed  Google Scholar 

  31. Chappard D, Legrand E, Basle MF et al (1996) Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 11:676–685. https://doi.org/10.1002/jbmr.5650110516

    Article  CAS  PubMed  Google Scholar 

  32. Dalle Carbonare L, Arlot ME, Chavassieux PM et al (2001) Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16:97–103. https://doi.org/10.1359/jbmr.2001.16.1.97

    Article  CAS  PubMed  Google Scholar 

  33. Van Staa TP, Laan RF, Barton IP et al (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229. https://doi.org/10.1002/art.11283

    Article  CAS  PubMed  Google Scholar 

  34. Sato AY, Richardson D, Cregor M, Davis HM, Au ED, McAndrews K, Zimmers TA, Organ JM, Peacock M, Plotkin LI, Bellido T (2017) Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases. Endocrinology 158:664–677. https://doi.org/10.1210/en.2016-1779

    Article  PubMed  PubMed Central  Google Scholar 

  35. Pearce G, Tabensky DA, Delmas PD, Baker HWG, Seeman E (1998) Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 83:801–806. https://doi.org/10.1210/jcem.83.3.4621

    Article  CAS  PubMed  Google Scholar 

  36. Richy F, Ethgen O, Bruyere O, Reginster J-Y (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301–310. https://doi.org/10.1007/s00198-003-1570-5

    Article  CAS  PubMed  Google Scholar 

  37. de Nijs RNJ, Jacobs JWG, Algra A, Lems WF, Bijlsma JWJ (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15:589–602. https://doi.org/10.1007/s00198-004-1614-5

    Article  CAS  PubMed  Google Scholar 

  38. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG, Lane N, Correa-Rotter R, Yanover M, Westhovens R, Epstein S, Adachi JD, Poubelle P, Melo-Gomes J, Rodriguez-Portales JA (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med 339:292–299. https://doi.org/10.1056/NEJM199807303390502

    Article  CAS  PubMed  Google Scholar 

  39. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039. https://doi.org/10.1056/NEJMoa071408

    Article  CAS  PubMed  Google Scholar 

  40. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006–1013. https://doi.org/10.1359/jbmr.2000.15.6.1006

    Article  CAS  PubMed  Google Scholar 

  41. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318. https://doi.org/10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K

    Article  CAS  PubMed  Google Scholar 

  42. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PEE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MOR, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211. https://doi.org/10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W

    Article  CAS  PubMed  Google Scholar 

  43. Stoch SA, Saag KG, Greenwald M et al (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36:1705–1714. https://doi.org/10.3899/jrheum.081207

    Article  CAS  PubMed  Google Scholar 

  44. Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69:242–247. https://doi.org/10.1007/s00223-001-1060-8

    Article  CAS  PubMed  Google Scholar 

  45. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277–285. https://doi.org/10.1007/s002230001146

    Article  CAS  PubMed  Google Scholar 

  46. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F (2003) Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 14:801–807. https://doi.org/10.1007/s00198-003-1425-0

    Article  CAS  PubMed  Google Scholar 

  47. Shin K, Park S-H, Park W et al (2017) Monthly oral ibandronate reduces bone loss in Korean women with rheumatoid arthritis and osteopenia receiving long-term glucocorticoids: a 48-week double-blinded randomized placebo-controlled investigator-initiated trial. Clin Ther 39:268–278.e2. https://doi.org/10.1016/j.clinthera.2017.01.008

    Article  CAS  PubMed  Google Scholar 

  48. Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, Obermayer-Pietsch BM, Pilz S, Dimai HP, Prenner G, Tscheliessnigg KH, Hauge E, Portugaller RH, Dobnig H (2009) Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 24:1335–1344. https://doi.org/10.1359/jbmr.090216

    Article  CAS  PubMed  Google Scholar 

  49. Reid DM, Devogelaer J-P, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253–1263. https://doi.org/10.1016/S0140-6736(09)60250-6

    Article  CAS  PubMed  Google Scholar 

  50. Axelsson KF, Nilsson AG, Wedel H, Lundh D, Lorentzon M (2017) Association between alendronate use and hip fracture risk in older patients using oral prednisolone. JAMA 318:146–155. https://doi.org/10.1001/jama.2017.8040

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Allen CS, Yeung JH, Vandermeer B, Homik J (2016) Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev 10:CD001347. https://doi.org/10.1002/14651858.CD001347.pub2

    Article  PubMed  Google Scholar 

  52. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, el Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, on behalf of the International Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3–23. https://doi.org/10.1002/jbmr.2405

    Article  PubMed  Google Scholar 

  53. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MCH, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23. https://doi.org/10.1002/jbmr.1998

    Article  PubMed  Google Scholar 

  54. Koh JH, Myong JP, Yoo J, Lim YW, Lee J, Kwok SK, Park SH, Ju JH (2017) Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years’ experience in a single center. Osteoporos Int 28:3251–3259. https://doi.org/10.1007/s00198-017-4169-y

    Article  CAS  PubMed  Google Scholar 

  55. Horton DB, Haynes K, Denburg MR, Thacker MM, Rose CD, Putt ME, Leonard MB, Strom BL (2017) Oral glucocorticoid use and osteonecrosis in children and adults with chronic inflammatory diseases: a population-based cohort study. BMJ Open 7:e016788. https://doi.org/10.1136/bmjopen-2017-016788

    Article  PubMed  PubMed Central  Google Scholar 

  56. Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445–454. https://doi.org/10.1016/S2213-8587(18)30075-5

    Article  CAS  PubMed  Google Scholar 

  57. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32:1291–1296. https://doi.org/10.1002/jbmr.3110

    Article  CAS  PubMed  Google Scholar 

  58. Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11–17. https://doi.org/10.1016/j.bone.2017.08.003

    Article  PubMed  Google Scholar 

  59. Oxlund H, Ortoft G, Thomsen JS et al (2006) The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 39:244–252. https://doi.org/10.1016/j.bone.2006.01.142

    Article  CAS  PubMed  Google Scholar 

  60. Devogelaer J-P, Adler RA, Recknor C et al (2010) Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 37:141–148. https://doi.org/10.3899/jrheum.090411

    Article  CAS  PubMed  Google Scholar 

  61. Saag KG, Agnusdei D, Hans D et al (2016) Trabecular bone score in patients with chronic glucocorticoid therapy-induced osteoporosis treated with alendronate or teriparatide. Arthritis Rheumatol 68:2122–2128. https://doi.org/10.1002/art.39726

    Article  CAS  PubMed  Google Scholar 

  62. Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR (2009) Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 20:2095–2104. https://doi.org/10.1007/s00198-009-0917-y

    Article  CAS  PubMed  Google Scholar 

  63. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441. https://doi.org/10.1056/NEJM200105103441904

    Article  CAS  PubMed  Google Scholar 

  64. Saag KG, Zanchetta JR, Devogelaer J-P, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346–3355. https://doi.org/10.1002/art.24879

    Article  CAS  PubMed  Google Scholar 

  65. Glüer C-C, Marin F, Ringe JD, Hawkins F, Möricke R, Papaioannu N, Farahmand P, Minisola S, Martínez G, Nolla JM, Niedhart C, Guañabens N, Nuti R, Martín-Mola E, Thomasius F, Kapetanos G, Peña J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset PK (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 28:1355–1368. https://doi.org/10.1002/jbmr.1870

    Article  CAS  PubMed  Google Scholar 

  66. Mok CC, Ying KY, To CH et al (2011) Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 70:778–784. https://doi.org/10.1136/ard.2010.143453

    Article  CAS  PubMed  Google Scholar 

  67. Kung AW, Chan TM, Lau CS et al (1999) Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy. Rheumatology (Oxford) 38:1239–1244. https://doi.org/10.1093/rheumatology/38.12.1239

    Article  CAS  Google Scholar 

  68. Hall GM, Daniels M, Doyle DV, Spector TD (1994) Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 37:1499–1505. https://doi.org/10.1002/art.1780371014

    Article  CAS  PubMed  Google Scholar 

  69. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical. trial J Clin Invest 102:1627–1633. https://doi.org/10.1172/JCI3914

    Article  CAS  PubMed  Google Scholar 

  70. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333. https://doi.org/10.1001/jama.288.3.321

    Article  CAS  PubMed  Google Scholar 

  71. Hall GM, Larbre JP, Spector TD et al (1996) A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol 35:568–573. https://doi.org/10.1093/rheumatology/35.6.568

    Article  CAS  PubMed  Google Scholar 

  72. Reid IR, Wattie DJ, Evans MC, Stapleton JP (1996) Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 156:1173–1177. https://doi.org/10.1001/archinte.156.11.1173

    Article  CAS  PubMed  Google Scholar 

  73. Crawford BAL, Liu PY, Kean MT, Bleasel JF, Handelsman DJ (2003) Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88:3167–3176. https://doi.org/10.1210/jc.2002-021827

    Article  CAS  PubMed  Google Scholar 

  74. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85:2670–2677. https://doi.org/10.1210/jcem.85.8.6731

    Article  CAS  PubMed  Google Scholar 

  75. Albaum JM, Lévesque LE, Gershon AS, Liu G, Cadarette SM (2015) Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996-2012. Osteoporos Int 26:2845–2852. https://doi.org/10.1007/s00198-015-3200-4

    Article  CAS  PubMed  Google Scholar 

  76. McKeown E, Bykerk VP, De Leon F et al (2012) Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology (Oxford) 51:1662–1669. https://doi.org/10.1093/rheumatology/kes079

    Article  CAS  Google Scholar 

  77. Beukelman T, Saag KG, Curtis JR, Kilgore ML, Pisu M (2010) Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. Osteoporos Int 21:1573–1584. https://doi.org/10.1007/s00198-009-1114-8

    Article  CAS  PubMed  Google Scholar 

  78. van Staa TP, Geusens P, Zhang B, Leufkens HGM, Boonen A, Cooper C (2007) Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatology (Oxford) 46:460–466. https://doi.org/10.1093/rheumatology/kel249

    Article  Google Scholar 

  79. Moriwaki K, Fukuda H (2019) Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan. Osteoporos Int. https://doi.org/10.1007/s00198-018-4798-9

  80. Adami S, Bianchi G, Brandi ML et al (2010) Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description. Clin Exp Rheumatol 28:561–570

    CAS  PubMed  Google Scholar 

  81. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397. https://doi.org/10.1007/s00198-007-0543-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809–816. https://doi.org/10.1007/s00198-010-1524-7

    Article  CAS  PubMed  Google Scholar 

  83. Buckley L, Guyatt G, Fink HA et al (2017) 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumat 69:1521–1537. https://doi.org/10.1002/art.40137

    Article  Google Scholar 

  84. Sutter S, Nishiyama KK, Kepley A, Zhou B, Wang J, McMahon DJ, Guo XE, Stein EM (2014) Abnormalities in cortical bone, trabecular plates, and stiffness in postmenopausal women treated with glucocorticoids. J Clin Endocrinol Metab 99:4231–4240. https://doi.org/10.1210/jc.2014-2177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Tang XL, Qin L, Kwok AW, Zhu TY, Kun EW, Hung VW, Griffith JF, Leung PC, Li EK, Tam LS (2013) Alterations of bone geometry, density, microarchitecture, and biomechanical properties in systemic lupus erythematosus on long-term glucocorticoid: a case-control study using HR-pQCT. Osteoporos Int 24:1817–1826. https://doi.org/10.1007/s00198-012-2177-5

    Article  CAS  PubMed  Google Scholar 

  86. Mellibovsky L, Prieto-Alhambra D, Mellibovsky F, Güerri-Fernández R, Nogués X, Randall C, Hansma PK, Díez-Perez A (2015) Bone tissue properties measurement by reference point indentation in glucocorticoid-induced osteoporosis. J Bone Miner Res 30:1651–1656. https://doi.org/10.1002/jbmr.2497

    Article  CAS  PubMed  Google Scholar 

  87. Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43. https://doi.org/10.1007/s11657-017-0324-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Geusens PP, de Nijs RNJ, Lems WF et al (2004) Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 63:324–325. https://doi.org/10.1136/ard.2003.008060

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Briot K, Cortet B, Roux C, Fardet L, Abitbol V, Bacchetta J, Buchon D, Debiais F, Guggenbuhl P, Laroche M, Legrand E, Lespessailles E, Marcelli C, Weryha G, Thomas T, Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO) (2014) 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine 81:493–501. https://doi.org/10.1016/j.jbspin.2014.10.001

    Article  PubMed  Google Scholar 

  90. Devogelaer J-P, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY, Rozenberg S, Boutsen Y (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17:8–19. https://doi.org/10.1007/s00198-005-2032-z

    Article  CAS  PubMed  Google Scholar 

  91. Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, Ozono K, Sagawa A, Takayanagi R, Tanaka H, Miki T, Masunari N, Tanaka Y (2014) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 32:337–350. https://doi.org/10.1007/s00774-014-0586-6

    Article  PubMed  Google Scholar 

  92. Rossini M, Adami S, Bertoldo F, Diacinti D, Gatti D, Giannini S, Giusti A, Malavolta N, Minisola S, Osella G, Pedrazzoni M, Sinigaglia L, Viapiana O, Isaia GC (2016) Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 68:1–39. https://doi.org/10.4081/reumatismo.2016.870

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 510 20th Street South, Faculty Office Tower 820D, Birmingham, AL, 35294, USA

    G. Adami & K. G. Saag

  2. Rheumatology Unit, University of Verona, Pz Scuro 10, 37135, Verona, Italy

    G. Adami

Authors
  1. G. Adami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. G. Saag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. G. Saag.

Ethics declarations

Conflict of interest

Giovanni Adami declares that he has no conflict of interest. Kenneth G Saag declares research grant from Amgen and Merck and consultant fee from Amgen, Lilly, Merck, and Radius.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adami, G., Saag, K. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 30, 1145–1156 (2019). https://doi.org/10.1007/s00198-019-04906-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-019-04906-x

Keywords

Search

Navigation